N/A
N=134
CAFE Study - Cancer Patient Fracture Evaluation
Cancer · Spinal Fractures
Bottom Line
View on ClinicalTrials.gov: NCT00211237 ↗Enrolled (actual)
134
Serious AEs
19.4%
Results posted
May 2010
Primary outcome: Primary: The Functional Status, as Measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 Month — 17.6; 18.2; 9.1; 18.0 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Balloon Kyphoplasty (Device); Non Surgical Management (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Medtronic Spine LLC
- Primary completion
- Apr 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Functional Status, as Measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 Month |
17.6; 18.2; 9.1; 18.0; -8.3; 0.1 | — |
| SECONDARY Change in Roland-Morris Disability Questionnaire Score |
17.6; 17.9; 18.3; -8.3; 0.3; -7.3 | — |
| SECONDARY Change in Functional Status Assessed With the Karnofsky Performance Scale |
57.1; 55.0; 58.7; 15.9; 0.0; 19.2 | — |
| SECONDARY Change in Functional Status Assessed With the Karnofsky Performance Scale |
57.1; 55.0; 58.7; 15.9; 0.0; 19.2 | — |
| SECONDARY Change in Back Pain |
7.3; 6.8; 7.6; -3.8; -0.7; -4.0 | — |
| SECONDARY Change in Back Pain |
7.3; 6.8; 7.6; -3.8; -0.7; -4.0 | — |
| SECONDARY Change in Quality of Life. |
25.4; 24.8; 35.2; 26.0; 9.4; 1.0 | — |
| SECONDARY Change in Quality of Life |
25.4; 25.3; 24.5; 9.4; -0.2; 9.1 | — |
| SECONDARY Change in Activities of Daily Living - Activities Reduced Due to Back Pain in Previous 2 Weeks |
90; 96; 97; 8.8; 4.3; 2.6 | — |
| SECONDARY Change in Activities of Daily Living - Activities Reduced Due to Back Pain in Previous 2 Weeks |
90; 96; 97; 8.8; 4.3; 2.6 | — |
| SECONDARY Change in Activities of Daily Living - Number of Days With Reduced Activities Due to Back Pain in Previous 2 Weeks |
10.8; 12.0; 11.0; -5.2; -0.4; -5.6 | — |
| SECONDARY Change in Activities of Daily Living - Number of Days With Reduced Activities Due to Back Pain in Previous 2 Weeks |
10.8; 12.0; 11.0; -5.2; -0.4; -5.6 | — |
| SECONDARY Change in Activities of Daily Living - Number of Days in Bed Due to Back Pain in Previous 2 Weeks |
6.3; 8.1; 5.8; -4.0; -0.2; -4.5 | — |
| SECONDARY Change in Activities of Daily Living - Number of Days in Bed Due to Back Pain in Previous 2 Weeks |
6.3; 8.1; 5.8; -4.0; -0.2; -4.5 | — |
| SECONDARY Ambulatory Status Change From Baseline to One Month |
56; 56; 32; 34; 10; 8.2 | — |
| SECONDARY Ambulatory Status Change |
56; 57; 55; 32; 30; 39 | — |
| SECONDARY Index Spinal Deformity Change Measured by Index Vertebral Body Angles From Baseline to 1 Month |
9.523; 10.501; 0.135; -0.598; 50.976; 51.390 | — |
| SECONDARY Index Spinal Deformity Change Measured by Index Vertebral Body Angles |
9.523; 10.806; 11.005; 1.312; NA; 1.438 | — |
| SECONDARY Index Spinal Deformity Change Measured by Index Vertebral Body Height Ratio |
0.744; 0.767; 0.741; 0.060; NA; 0.024 | — |
| SECONDARY Index Spinal Deformity Change Measured by Index Vertebral Body Height Ratio |
0.744; 0.767; 0.741; 0.060; NA; 0.024 | — |
| SECONDARY Back Pain Analgesics Used |
96; 78; 87; 82; 61; 68 | — |
| SECONDARY Back Pain Analgesics Used |
96; 78; 87; 82; 61; 68 | — |
| SECONDARY Change in Neurology Status From Baseline (Motor Strength) |
8.8; 3.3; 84; 74; 1.5; 3.3 | — |
| SECONDARY Change in Neurology Status From Baseline (Motor Strength)-Per Protocol |
8.8; 8.7; 2.6; 84; 39; 92 | — |
| SECONDARY Change in Neurological Status From Baseline (Sensory Examination) |
2.9; 0.0; 2.6; 91; 52; 95 | — |
| SECONDARY Change in Neurological Status From Baseline (Sensory Examination) |
2.9; 0.0; 2.6; 91; 52; 95 | — |
| SECONDARY Change in Neurological Status From Baseline (Reflex Strength) |
7.4; 4.3; 5.3; 85; 43; 82 | — |
| SECONDARY Change in Neurological Status From Baseline (Reflex Strength) |
7.4; 4.3; 5.3; 85; 43; 82 | — |
| SECONDARY Change in Neurological Status From Baseline (Limb Strength) |
12; 0.0; 16; 81; 48; 82 | — |
| SECONDARY Change in Neurological Status From Baseline (Limb Strength) |
12; 0.0; 16; 81; 48; 82 | — |
| SECONDARY Rate of Study Treatment-related Adverse Events Within 30 Days of Baseline |
33; 30; 1.4; 0; 4.3; 0 | — |
| SECONDARY Rate of Study Treatment-related Adverse Events Till Study Completion |
77; 50; 37; 79; 1.4; 0 | — |
| SECONDARY Rate of Subsequent Vertebral Body Fractures |
19.4; 23.1; 11.8; 13.2; 0.0; 7.4 | — |
| SECONDARY Rate of Subsequent Vertebral Body Fractures |
19.4; 23.1; 11.8; 13.2; 0.0; 7.4 | — |
Summary
The primary objective of this study is to evaluate the safety and effectiveness of balloon kyphoplasty treatment for painful, acute, vertebral compression fractures (VCFs) as compared to standard non-surgical therapy in patients with cancer.
Eligibility Criteria
Inclusion Criteria
- One to 3 painful (pain on palpation/percussion over fractured vertebral body) VCF(s), T5-L5, with either bone marrow edema imaged by magnetic resonance imaging (MRI) or a fracture imaged by plain radiographs using the method of Genant
- Pain NRS score ≥4 on a scale of 0 to 10
- When the patient is newly diagnosed with multiple myeloma, the pain assessment must not be done until after completion of at least one pulse of steroid therapy or one week after the initiation of active multiple myeloma therapy.
- Roland Morris Disability Questionnaire score ≥ 10 on a scale of 0 to 24
- Patients must be at least 21 years old.
- No change in chemotherapy regimen (change in dose(s) permitted) for 1 month prior to enrollment
- No change in chemotherapy regimen (change in dose(s) permitted) planned for at least 1 month following enrollment
- No major surgery to the spine planned for at least 1 month following enrollment
- Life expectancy of ≥ 3 months
- Patient has sufficient mental capacity to comply with the protocol requirements
- Patient has stated availability for all study visits
- Patient is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent.
Exclusion Criteria
- Patients with primary tumors of the bone (e.g., osteosarcoma) or solitary plasmacytoma at site of the index VCF. Patients with these tumors in anatomic sites other than the index VCF are eligible.
- Concurrent Phase I investigational anti-cancer treatment
- Significant clinical morbidities (aside from the index fracture(s) and cancer) that may potentially interfere with the collection of data concerning pain and function
- VCF morphology deemed unsuitable for balloon kyphoplasty
- Additional non-kyphoplasty surgical treatment is required for the index fracture
- Patients requiring the use of high-dose steroid (≥ 100 mg prednisone or 20 mg dexamethasone per day), intravenous (IV) pain medication, or nerve block to control chronic back pain unrelated to index VCF(s). Patients who receive high-dose steroids for treatment of their cancer (for at least 30 days) are eligible.
- Patients with a platelet count of < 20,000 measured at the time of hospital admission for the procedure
- Spinal cord compression or canal compromise requiring decompression
- Patients with osteoblastic tumors at the site of index VCF. Patients with osteoblastic tumors outside of vertebral levels intended for kyphoplasty may be enrolled.
- Medical/surgical conditions contrary to the balloon kyphoplasty procedure (e.g., in the presence of active or incompletely treated local infection)
- Known allergy to bone cement or contrast medium used in the treatment of study subjects
- MRI contraindication (e.g., cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis)
- Positive baseline pregnancy test (for women of child-bearing potential)
- Patients who may require allogeneic bone marrow transplantation during the course of the study.
Other Reasons for Lack of Enrollment:
A. Patient is afraid to have surgery
B. Patient is afraid to have anesthesia
C. Patient/family is not willing to participate in research
D. Patient is not willing to be randomized
Data sourced from ClinicalTrials.gov (NCT00211237). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.